Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 9, 2017, Pages 1427-1434.e2

  Battat, Robert ^a,b   Kopylov, Uri ^c   Bessissow, Talat ^b   Bitton, Alain ^b   Cohen, Albert ^a   Jain, Anjali ^d   Martel, Myriam ^b   Seidman, Ernest ^b   Afif, Waqqas ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c TEL AVIV UNIVERSITY   (Israel)

^d Prometheus Laboratories Inc   (United States)

Author keywords

Biologic; Inflammatory Bowel Disease; Therapeutic Drug Monitoring; UNITI

Indexed keywords

BIOLOGICAL MARKER; IMMUNOLOGIC FACTOR; USTEKINUMAB;

ADOLESCENT; ADULT; AGED; CHILD; COLONOSCOPY; CROHN DISEASE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; PROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CHILD; CHILD, PRESCHOOL; COLONOSCOPY; CROHN DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; USTEKINUMAB; YOUNG ADULT;

EID: 85027573700     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2017.03.032     Document Type: Article

References (37)

1. Baumgart, D.C., Sandborn, W.J., Crohn's disease. Lancet 380 (2012), 1590–1605.
2. Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002), 1541–1549.
3. Hanauer, S.B., Sandborn, W.J., Rutgeerts, P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 (2006), 323–333 quiz 591.
4. Colombel, J.F., Sandborn, W.J., Rutgeerts, P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 (2007), 52–65.
5. Sandborn, W.J., Feagan, B.G., Stoinov, S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357 (2007), 228–238.
6. Schreiber, S., Khaliq-Kareemi, M., Lawrance, I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357 (2007), 239–250.
7. Duerr, R.H., Taylor, K.D., Brant, S.R., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314 (2006), 1461–1463.
8. Neurath, M.F., IL-23: a master regulator in Crohn disease. Nat Med 13 (2007), 26–28.
9. Wang, K., Zhang, H., Kugathasan, S., et al. Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn disease. Am J Hum Genet 84 (2009), 399–405.
10. Sandborn, W.J., Feagan, B.G., Fedorak, R.N., et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135 (2008), 1130–1141.
11. Sandborn, W.J., Gasink, C., Gao, L.L., et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 367 (2012), 1519–1528.
12. Kopylov, U., Afif, W., Cohen, A., et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease–the McGill experience. J Crohn's Colitis 8 (2014), 1516–1522.
13. Feagan, B.G., Sandborn, W.J., Gasink, C., et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med 375 (2016), 1946–1960.
14. Biotech, Inc. Janssen. FDA Approves STELARA® (ustekinumab) for treatment pf adults with moderately to severely active Crohn's disease. Available at: https://www.jnj.com/media-center/press-releases/fda-approves-stelara-ustekinumab-for-treatment-of-adults-with-moderately-to-severely-active-crohns-disease. Accessed October 23, 2016.
15. Khorrami, S., Ginard, D., Marín-Jiménez, I., et al. Ustekinumab for the treatment of refractory Crohn's disease: the Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis 22 (2016), 1662–1669.
16. Wils, P., Bouhnik, Y., Michetti, P., et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn's disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol 14 (2016), 242–250.e1–e2.
17. Harris, K.A., Horst, S., Gadani, A., et al. Patients with refractory Crohn's disease successfully treated with ustekinumab. Inflamm Bowel Dis 22 (2016), 397–401.
18. UEG Week 2016 Oral Presentations. United European Gastroenterol J 4:5 Suppl (2016), A1–A156.
19. Afif, W., Loftus, E.V., Faubion, W.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 105 (2010), 1133–1139.
20. Afif, W., Leighton, J.A., Hanauer, S.B., et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 15 (2009), 1302–1307.
21. Khanna, R., Sattin, B., Afif, W., et al. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther 38 (2013), 447–459.
22. Adedokun, O.J., Xu, Z., Gasink, C., et al. Sa1934 Pharmacokinetics and exposure-response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: results from the UNITI-1, UNITI-2, and IM-UNITI Studies. Gastroenterology, 150(Suppl 1), 2016, S408.
23. Salbato, J., Westin, S., Hester, K.D., et al. Tu1311 Validation of a homogenous mobility shift assay (HMSA) for the measurement of ustekinumab (UTK) and antibodies-to-ustekinumab (ATU) in inflammatory bowel disease (IBD) patient serum. Gastroenterology, 148(Suppl 1), 2015, S-856.
24. Kopylov, U., Yung, D.E., Engel, T., et al. Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 28 (2016), 1137–1144.
25. Kopylov, U., Rosenfeld, G., Bressler, B., Seidman, E., Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis 20 (2014), 742–756.
26. Vuitton, L., Marteau, P., Sandborn, W.J., et al. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut 65 (2016), 1447–1455.
27. Kopylov, U., Ben-Horin, S., Seidman, E., Therapeutic drug monitoring in inflammatory bowel disease. Ann Gastroenterol 27 (2014), 304–312.
28. Shah, S.C., Colombel, J.F., Sands, B.E., Narula, N., Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther 43 (2016), 317–333.
29. Khanna, R., Bressler, B., Levesque, B.G., et al. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet 386 (2015), 1825–1834.
30. Colombel, J.F., Keir, M.E., Scherl, A., et al. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut, 2016 Sep 2 http://dx.doi.org/10.1136/gutjnl-2016-312307 [e-pub ahead of print].
31. Modigliani, R., Mary, J.Y., Simon, J.F., et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 98 (1990), 811–818.
32. Daperno, M., D'Haens, G., Van Assche, G., et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 60 (2004), 505–512.
33. Jones, J., Loftus, E.V. Jr., Panaccione, R., et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 6 (2008), 1218–1224.
34. Peyrin-Biroulet, L., Reinisch, W., Colombel, J.F., et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 63 (2014), 88–95.
35. Schellekens, H., The immunogenicity of therapeutic proteins. Discov Med 9 (2010), 560–564.
36. Zhou, H., Hu, C., Zhu, Y., et al. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 50 (2010), 257–267.
37. Zhu, Y., Hu, C., Lu, M., et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 49 (2009), 162–175.